From our survey

Why 59 percent weigh FDA approval, and what it means for your plan

When we started reading the survey results, we expected price and convenience to dominate. They did matter. But a quieter factor kept showing up alongside them: whether a depression treatment carries FDA approval. For a lot of people, those three letters seem to function as a kind of permission.

This is the story of that finding, and why it matters in a practical way if you have commercial insurance through an employer or the marketplace.

The number

Our survey reached 443 adults in ten Midwest states, stretching from Missouri and Illinois north to Minnesota and Wisconsin. Every result here is final, from Pollfish's validated data. One question asked how heavily FDA approval would weigh on a decision to try a new depression treatment.

Nineteen percent called it the deciding factor. Another 40 percent called it a big factor. Put together, that is 59 percent for whom FDA approval carries real weight. People with commercial insurance, 173 of our respondents, weighed it a little less, at 54 percent. A further 27 percent said it would matter some. Just 14 percent waved it away as irrelevant.

Read that last figure again. Fewer than one person in seven was indifferent to FDA status. In a region known for practical skepticism, that is close to a consensus.

Trust, not enthusiasm

What the finding seems to capture is caution. On first hearing that ketamine might be used against depression or PTSD, 34 percent of respondents landed on cautious but open, more than chose any other answer. Another 21 percent were skeptical. People are not rushing toward new treatments. They are looking for a reason to trust one, and FDA approval is among the clearest signals available to them.

That makes sense. Most people cannot evaluate clinical trial data. They can, however, understand that a federal regulator reviewed the evidence for a specific use and signed off.

Where the story turns practical

For people with commercial insurance, FDA status is not only a trust signal. It is often tied to whether a treatment gets covered at all.

Insurers generally build their coverage policies around FDA-approved uses. A treatment used for its approved purpose, with the right documentation, has a defined path to coverage, usually through prior authorization. A treatment used off-label, meaning for a purpose the FDA has not approved, is more likely to be denied or left to the patient to pay. That is not a legal rule that applies everywhere, and plans vary, but it is a common pattern.

That connects directly to what respondents told us about money. When they ranked what matters in a provider, 85 percent placed insurance coverage among their top two. Asked how much insurance would factor into trying a treatment, 22 percent called it deciding and 43 percent called it big. FDA status and insurance coverage are two separate questions, but for someone on a commercial plan they often lead to the same answer.

What this looks like with depression treatments

Take the treatments that come up most in conversations about hard-to-treat depression:

• Esketamine (Spravato) earned FDA approval as a treatment for depression that has outlasted other options. Patients use the nasal spray inside a certified clinic and stay for two or more hours of observation. Commercial plans commonly cover it with prior authorization, and Brain Recovery Centers explains how a supervised Spravato visit works.
• IV ketamine has FDA approval only as an anesthetic; prescribing it to treat depression falls outside that label. Coverage for that use is less consistent, and many patients pay out of pocket.
• At-home ketamine, often from compounding pharmacies, is not FDA-approved for depression. The FDA has publicly warned about risks when compounded ketamine is used without monitoring.
• TMS is a device, so the FDA clears it rather than approving it, for adults whose depression has not lifted on antidepressants. Many commercial plans cover it after prior authorization.

One more piece of context. Our poll found Spravato unknown by name to 73 percent, and a mere 6 percent knew what it actually does. The ketamine relative that did earn FDA approval is, oddly, the one hardly anyone can name.

What approval does not mean

It is worth being careful here, because a trust signal can be over-read. FDA approval means regulators weighed the evidence and accepted it for a stated use in a stated group of patients. It is not a promise of results for you. It is not a statement that every person can take it safely. And it says nothing about whether your plan will pay without conditions.

Whether any of this suits you belongs in a conversation with a clinician who has seen your records.

What to do with this if you have commercial coverage

• Ask what the treatment is approved or cleared for. Then ask whether your situation matches that use.
• Ask your plan for the medical policy on the specific treatment. It lists the criteria your doctor will need to document.
• Ask which benefit applies. Some treatments run through the medical benefit, some through a specialty pharmacy, and some split the drug and the visit. Each can carry different cost sharing.
• Check manufacturer savings programs. For some approved drugs, including esketamine, the manufacturer offers savings for commercially insured patients. Ask what the program covers and what it does not.
• Ask for the price in writing, covering the whole course rather than one visit.

The person to ask

The same survey offers one more clue about where this should happen. Nothing else came close to one answer: 74 percent of respondents would give a new treatment a try if their own doctor suggested it. That is where the FDA question belongs. Your doctor can tell you what a treatment is approved for, whether you fit, and how your plan is likely to treat it.

Treat this piece as general information rather than medical advice.

If suicidal thoughts are part of your days right now, please do not let paperwork or appointment dates hold you back. No FDA label or prior authorization stands between you and 988, the Suicide and Crisis Lifeline, which takes calls and texts free at every hour.

Methodology

We commissioned this study, and the publisher paid for it. The fieldwork happened on Pollfish's consumer panel; by its close on June 23, 2026, it held finished answers from 443 people between 18 and 64. They live in Iowa, Oklahoma, Missouri, Wisconsin, Kansas, Indiana, Illinois, Minnesota, Nebraska, and Ohio. Aside from the commercial insurance group, figures describe all respondents, and they are final now that the panel is validated.